文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

微小RNA-499通过调控肌球蛋白重链基因轴改善脓毒症心肌功能障碍

[MicroRNA-499 improved septic myocardial dysfunction by regulating myosin heavy chain gene axis].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2022-01-01
一句话结论大鼠实验显示,miR-499激动剂预处理可上调α-MHC、下调β-MHC,改善脓毒症心肌功能障碍,作者认为靶向调控miR-499可能是治疗SMD的有效途径。

该研究将60只健康成年雄性SD大鼠随机分为PBS对照组、LPS诱导SMD模型组、miR-499激动剂预处理组和miR-499抑制剂预处理组,每组15只。SMD模型通过腹腔注射LPS 10 mg/kg复制;两个预处理组分别经尾静脉注射agomir 30 mg/kg或antagomir 80 mg/kg,连续3天、每天1次;PBS组和LPS组不预处理。LPS注射后5小时行超声心动图、qPCR、Western blotting和电化学发光检测。结果显示,与LPS组相比,agomir预处理组LVEF和LVFS显著升高,β-MHC蛋白表达显著下调,α-MHC蛋白表达显著上调,血浆NT-proBNP显著降低;antagomir预处理组则相反。作者认为,miR-499可调控α-MHC和β-MHC表达,从而改善脓毒症所致心功能障碍,靶向调控miR-499表达可能是治疗SMD的有效途径。

要点

  • 在LPS 10 mg/kg腹腔注射诱导的SMD大鼠模型中,agomir预处理组LVEF为0.662±0.020、LVFS为(36.16±1.43)%,均显著高于LPS组的0.323±0.024和(20.20±1.32)%(均P<0.01)。
  • agomir预处理组β-MHC/GAPDH为0.74±0.04,显著低于LPS组的2.97±0.34(P<0.01);α-MHC/GAPDH为1.59±0.05,显著高于LPS组的0.74±0.14(P<0.01)。
  • agomir预处理组血浆NT-proBNP为(114.49±6.85)ng/L,显著低于LPS组的(334.13±4.36)ng/L(P<0.01)。
  • antagomir预处理组LVEF为0.297±0.021、LVFS为(19.38±1.52)%,均显著低于LPS组的0.323±0.024和(21.20±1.32)%(均P<0.01);α-MHC/GAPDH为0.63±0.03,显著低于LPS组的0.74±0.14(P<0.01);β-MHC/GAPDH为3.03±0.47,显著高于LPS组的2.97±0.34(P<0.01);
  • 作者认为,miR-499可调控α-MHC和β-MHC表达,从而改善脓毒症所致心功能障碍,靶向调控miR-499表达可能是治疗SMD的有效途径。

适用人群与场景

  • 健康成年雄性Sprague-Dawley(SD)大鼠,共60只,随机分为4组,每组15只。
  • 研究场景为动物实验,非急诊或ICU患者人群。

处置流程与药物剂量

  • SMD大鼠模型复制:腹腔注射LPS 10 mg/kg;PBS组腹腔注射等量PBS。
  • miR-499激动剂预处理:经尾静脉注射agomir 30 mg/kg,连续3天,每天1次。
  • miR-499抑制剂预处理:经尾静脉注射antagomir 80 mg/kg,连续3天,每天1次。
  • PBS组和LPS组不预处理;LPS注射后5小时行超声心动图检测。

研究设计与关键结果

  • 研究类型:动物实验;样本量:60只健康成年雄性SD大鼠;分组:PBS对照组、LPS诱导SMD模型组、miR-499激动剂预处理组(agomir+LPS组)、miR-499抑制剂预处理组(antagomir+LPS组),每组15只。
  • 与PBS组相比,LPS组大鼠精神萎靡;LPS下调血浆和心肌组织miR-499水平,降低心肌组织α-MHC表达,上调β-MHC表达。
  • 与PBS组相比,LPS组超声心动图LVEF、LVFS、CO、SV和HR分别降低49.1%、59.2%、48.8%、39.4%和15.9%,血浆NT-proBNP水平显著升高,提示LPS可诱导大鼠心功能障碍。
  • 与LPS组相比,agomir预处理过表达miR-499后,LVEF和LVFS显著升高[LVEF:0.662±0.020 vs. 0.323±0.024,LVFS:(36.16±1.43)% vs.(20.20±1.32)%,均P<0.01];β-MHC蛋白表达显著下调(β-MHC/GAPDH:0.74±0.04 vs. 2.97±0.34,P<0.01),α-MHC蛋白表达显著上调(α-MHC/GAPDH:1.59±0.05 vs. 0.74±0.14,P<0.01),血浆NT-proBNP水平显著降低[ng/L:114.49±6.85 vs. 334.13±4.36,P<0.01]。
  • 与LPS组相比,antagomir抑制miR-499表达后,LVEF和LVFS显著降低[LVEF:0.297±0.021 vs. 0.323±0.024,LVFS:(19.38±1.52)% vs.(21.20±1.32)%,均P<0.01],提示大鼠心功能显著受抑制;α-MHC蛋白表达显著下调(α-MHC/GAPDH:0.63±0.03 vs. 0.74±0.14,P<0.01),β-MHC蛋白表达显著上调(β-MHC/GAPDH:3.03±0.47 vs. 2.97±0.34,P<0.01),血浆NT-proBNP水平显著升高[ng/L:373.91±4.23 vs. 334.13±4.36,P<0.05]。

证据类型、等级与局限

  • 证据类型:动物实验(大鼠)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,miR-499可调控α-MHC和β-MHC表达,从而改善脓毒症所致心功能障碍;靶向调控miR-499表达可能是治疗SMD的有效途径。
  • 该研究为LPS诱导SMD大鼠模型,agomir和antagomir均为预处理给药,非急诊或ICU临床推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the role and mechanism of microRNA-499 (miR-499) regulating α-myosin heavy chain (α-MHC) and β-myosin heavy chain (β-MHC) gene axis in septic myocardial dysfunction (SMD) and its significance.

METHODS: Sixty healthy adult male Sprague-Dawley (SD) rats were divided into phosphate buffered saline (PBS) control group (PBS group), lipopolysaccharide (LPS) induced SMD model group (LPS group), miR-499 agonist pretreatment group (agomir+LPS group), and miR-499 inhibitor pretreatment group (antagomir+LPS group) by random number table, with 15 rats in each group. SMD rat model was reproduced by intraperitoneal injection of LPS 10 mg/kg. The PBS group was intraperitoneally injected with the same amount of PBS. The two pretreatment groups were injected with agomir 30 mg/kg or antagomir 80 mg/kg through the caudal vein for 3 days, once a day. PBS group and LPS group were not pretreated. Echocardiography was detected 5 hours after LPS injection, and relevant indexes were recorded. The expression of miR-499 in plasma and myocardial tissue was detected by real-time quantitative polymerase chain reaction (qPCR). Western blotting was used to detect the protein expressions of α-MHC and β-MHC in myocardial tissue. Plasma N-terminal pro-brain natriuretic peptide (NT-proBNP), a marker of heart failure, was measured by electrochemiluminescence.

RESULTS: Compared with the PBS group, the rats in LPS group were depressed. Additionally, LPS down-regulated the level of miR-499 in plasma and myocardial tissue, decreased α-MHC expression in myocardial tissue and up-regulated the expression of β-MHC. Echocardiography showed that left ventricular ejection fraction (LVEF), left ventricle fractional shortening (LVFS), cardiac output (CO), stroke volume (SV) and heart rate (HR) decreased by 49.1%, 59.2%, 48.8%, 39.4% and 15.9%, respectively, and the level of plasma NT-proBNP increased significantly in LPS group, indicating that LPS could induce cardiac dysfunction in rats. Compared with the LPS group, after pretreatment with agomir to overexpress the miR-499, LVEF and LVFS were significantly increased [LVEF: 0.662±0.020 vs. 0.323±0.024, LVFS: (36.16±1.43)% vs. (20.20±1.32)%, both P < 0.01], which suggested that the cardiac function of rats was improved in agomir+LPS group. At the same time, pretreatment with agomir significantly down-regulated the β-MHC protein expression (β-MHC/GAPDH: 0.74±0.04 vs. 2.97±0.34, P < 0.01), significantly up-regulated α-MHC protein expression (α-MHC/GAPDH: 1.59±0.05 vs. 0.74±0.14, P < 0.01), and significantly decreased the plasma NT-proBNP level (ng/L: 114.49±6.85 vs. 334.13±4.36, P < 0.01). After pretreatment with antagomir to inhibit the expression of miR-499, echocardiography showed that LVEF and LVFS were significantly lower than those in the LPS group [LVEF: 0.297±0.021 vs. 0.323±0.024, LVFS: (19.38±1.52)% vs. (21.20±1.32)%, both P < 0.01], which suggested that the cardiac function of rats was significantly inhibited. At the same time, pretreatment with antagomir significantly down-regulated α-MHC protein expression in myocardial tissue (α-MHC/GAPDH: 0.63±0.03 vs. 0.74±0.14, P < 0.01), significantly up-regulated β-MHC protein expression (β-MHC/GAPDH: 3.03±0.47 vs. 2.97±0.34, P < 0.01), and significantly increased the level of plasma NT-proBNP (ng/L: 373.91±4.23 vs. 334.13±4.36, P < 0.05).

CONCLUSIONS: miR-499 could regulate the expression of α-MHC and β-MHC which improved cardiac dysfunction caused by sepsis. Targeted regulation of miR-499 expression may be an effective way to treat SMD.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Yang Y, Li Z, Ye H, et al. [MicroRNA-499 improved septic myocardial dysfunction by regulating myosin heavy chain gene axis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 35307061. doi:10.3760/cma.j.cn121430-20210706-01012

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。